Cargando…
The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial
INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287454/ https://www.ncbi.nlm.nih.gov/pubmed/32747012 http://dx.doi.org/10.1016/j.medcli.2020.06.007 |
_version_ | 1783545066242965504 |
---|---|
author | Cui, Haiming Wu, Feng Fan, Zhenyu Cheng, Xin Cheng, Jilin Fan, Min |
author_facet | Cui, Haiming Wu, Feng Fan, Zhenyu Cheng, Xin Cheng, Jilin Fan, Min |
author_sort | Cui, Haiming |
collection | PubMed |
description | INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. PATIENTS AND METHOD: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. RESULTS: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. CONCLUSIONS: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms. |
format | Online Article Text |
id | pubmed-7287454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72874542020-06-11 The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial Cui, Haiming Wu, Feng Fan, Zhenyu Cheng, Xin Cheng, Jilin Fan, Min Med Clin (Barc) Brief Report INTRODUCTION AND OBJECTIVE: A recent outbreak of coronavirus disease 2019 (COVID-19) occurs in the worldwide. Angiotensin-converting enzyme 2 (ACE2) can mediate coronavirus entry into host cells. Therefore, renin–angiotensin system inhibitors (RASI) were suspected of contributing to the increase of coronavirus infection. We aimed to analyze the effects of RASI in COVID-19 patients with hypertension. PATIENTS AND METHOD: In this retrospective, single-center study, 27 COVID-19 patients with hypertension, who were admitted to the Shanghai Public Health Clinical Center from January 25, 2020 to January 31, 2020, were analyzed for clinical features, laboratory parameters, medications and the length of stay. All the patients were given antiviral and antihypertension treatment, of which 14 patients were treated with RASI and 13 patients without RASI. RESULTS: Comparing the two groups, we did not found statistically significant differences in clinical symptoms and laboratory tests. Furthermore, cough was not aggravated. CONCLUSIONS: Through the analysis of this small sample, RASI could be deemed safe and effective to control high blood pressure of COVID-19 patients. Further analysis with a larger sampling size is required to explore the underlying mechanisms. The Authors. Published by Elsevier España, S.L.U. 2020-10-09 2020-06-11 /pmc/articles/PMC7287454/ /pubmed/32747012 http://dx.doi.org/10.1016/j.medcli.2020.06.007 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Brief Report Cui, Haiming Wu, Feng Fan, Zhenyu Cheng, Xin Cheng, Jilin Fan, Min The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title | The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title_full | The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title_fullStr | The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title_full_unstemmed | The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title_short | The effects of renin–angiotensin system inhibitors (RASI) in coronavirus disease (COVID-19) with hypertension: A retrospective, single-center trial |
title_sort | effects of renin–angiotensin system inhibitors (rasi) in coronavirus disease (covid-19) with hypertension: a retrospective, single-center trial |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287454/ https://www.ncbi.nlm.nih.gov/pubmed/32747012 http://dx.doi.org/10.1016/j.medcli.2020.06.007 |
work_keys_str_mv | AT cuihaiming theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT wufeng theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT fanzhenyu theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT chengxin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT chengjilin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT fanmin theeffectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT cuihaiming effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT wufeng effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT fanzhenyu effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT chengxin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT chengjilin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial AT fanmin effectsofreninangiotensinsysteminhibitorsrasiincoronavirusdiseasecovid19withhypertensionaretrospectivesinglecentertrial |